Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain

What Was Tested

This randomized controlled trial paper looks at Nafarelin in the context of endometriosis.

Who Took Part

PubMed indexes the participants as adults, women only.

One hundred seventy-nine women with pelvic pain and endometriosis.

Patients were assigned randomly to 3 months nafarelin followed by 3 months of placebo (n = 91) or to 6 months nafarelin (n = 88) in a prospective, randomized, double-blind multicenter trial.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

Random assignment meant chance, not the researchers, decided who got Nafarelin and who got the comparison, which limits bias.

As a double-blind Nafarelin study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Nafarelin, giving a reference point.

More than one site took part, so the participants came from several places.

The methods mention a period of 12 months.

Double-blind, prospective, multicenter, clinical trial.

Fifteen reproductive endocrine clinics throughout the United States.

Patients were followed for 12 months after cessation of therapy.

What Was Measured

The subject headings attached to it are Endometriosis, Estradiol, Nafarelin, Pelvic Pain and Recurrence.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Nafarelin in people with endometriosis over 12 months.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1995 (Fertility and sterility), a journal based in United States.

More context: the Nafarelin compound page, Endometriosis research.